Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug

Altimmune

05/01/2026 12:50

** Shares of drug developer Altimmune ALT.O rise 12.8% to $3.96 premarket

** ALT says U.S. FDA has granted "breakthrough therapy" tag for its experimental drug to treat patients with a type of liver disease

** The drug, pemvidutide, is being tested in patients with metabolic dysfunction-associated steatohepatitis or MASH — a serious liver disease that develops when fat buildup causes inflammation of the organ

** The breakthrough therapy tag is meant to speed up development and review of drugs to treat serious conditions or those with unmet medical needs

** Co says it plans to initiate a late-stage trial evaluating multiple pemvidutide doses over a 52-week treatment period

** In last 12 months, stock down 2.8%

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))